Publications

Export 5136 results:
Sort by: Author [ Title  (Desc)] Type Year
A B C [D] E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
D
Ali, M., A. Shohayeb, and waleed saber, Dual trigger versus single trigger in poor responders in GnRH antagonist ICSI cycles , , Cairo, Cairo University , 2018.
Khanaa, V., K. P. Thooyamani, and R. Udayakumar, "Dual Tree Complex Wavelet Transform for Adaptive Interferogram Residual Reduction", Middle-East Journal of Scientific Research, vol. 20, no. 9, pp. 1059–1064, 2014. Abstract
n/a
Toulany, M., M. Iida, S. Keinath, F. F. Iyi, K. Mueck, B. Fehrenbacher, W. Y. Mansour, M. Schaller, D. L. Wheeler, and P. H. Rodemann, "Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.", Oncotarget, vol. 7, issue 28, pp. 43746-43761, 2016 Jul 12. Abstract

Despite the significant contribution of radiotherapy to non-small lung cancer (NSCLC), radioresistance still occurs. One of the major radioresistance mechanisms is the hyperactivation of the PI3K/Akt pathway in which Akt facilitates the repair of DNA double-strand breaks (DSBs) through the stimulation of DNA-PKcs. We investigated if targeting PI3K would be a potential approach for enhancing the radiosensitivity of K-RAS mutated (K-RASmut) NSCLC cell lines A549 and H460. Short-term (1-2 h) pre-treatment of cells with the PI3K inhibitor PI-103 (1 μM) inhibited Akt/DNA-PKcs activity, blocked DSBs repair and induced radiosensitivity, while long-term (24 h) pre-treatment did not. Lack of an effect after 24 h of PI-103 pre-treatment was due to reactivation of K-Ras/MEK/ERK-dependent Akt. However, long-term treatment with the combination of PI-103 and MEK inhibitor PD98059 completely blocked reactivation of Akt and impaired DSBs repair through non-homologous end joining (NHEJ) leading to radiosensitization. The effect of PI3K inhibition on Akt signaling was also tested in A549 mouse xenografts. P-Akt and P-DNA-PKcs were inhibited 30 min post-irradiation in xenografts, which were pretreated by PI-103 30 min before irradiation. However, Akt was reactivated 30 min post-irradiation in tumors, which were pre-treated for 3 h with PI-103 before irradiation. After a 24 h pretreatment with PI-103, a significant reactivation of Akt was achieved 24 h after irradiation. Thus, due to MEK/ERK-dependent reactivation of Akt, targeting PI3K alone is not a suitable approach for radiosensitizing K-RASmut NSCLC cells, indicating that dual targeting of PI3K and MEK is an efficient approach to improve radiotherapy outcome.

Toulany, M., M. Iida, S. Keinath, F. F. Iyi, K. Mueck, B. Fehrenbacher, W. Y. Mansour, M. Schaller, D. L. Wheeler, and P. H. Rodemann, "Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.", Oncotarget, vol. 7, issue 28, pp. 43746-43761, 2016 Jul 12. Abstract

Despite the significant contribution of radiotherapy to non-small lung cancer (NSCLC), radioresistance still occurs. One of the major radioresistance mechanisms is the hyperactivation of the PI3K/Akt pathway in which Akt facilitates the repair of DNA double-strand breaks (DSBs) through the stimulation of DNA-PKcs. We investigated if targeting PI3K would be a potential approach for enhancing the radiosensitivity of K-RAS mutated (K-RASmut) NSCLC cell lines A549 and H460. Short-term (1-2 h) pre-treatment of cells with the PI3K inhibitor PI-103 (1 μM) inhibited Akt/DNA-PKcs activity, blocked DSBs repair and induced radiosensitivity, while long-term (24 h) pre-treatment did not. Lack of an effect after 24 h of PI-103 pre-treatment was due to reactivation of K-Ras/MEK/ERK-dependent Akt. However, long-term treatment with the combination of PI-103 and MEK inhibitor PD98059 completely blocked reactivation of Akt and impaired DSBs repair through non-homologous end joining (NHEJ) leading to radiosensitization. The effect of PI3K inhibition on Akt signaling was also tested in A549 mouse xenografts. P-Akt and P-DNA-PKcs were inhibited 30 min post-irradiation in xenografts, which were pretreated by PI-103 30 min before irradiation. However, Akt was reactivated 30 min post-irradiation in tumors, which were pre-treated for 3 h with PI-103 before irradiation. After a 24 h pretreatment with PI-103, a significant reactivation of Akt was achieved 24 h after irradiation. Thus, due to MEK/ERK-dependent reactivation of Akt, targeting PI3K alone is not a suitable approach for radiosensitizing K-RASmut NSCLC cells, indicating that dual targeting of PI3K and MEK is an efficient approach to improve radiotherapy outcome.

Gyebi, G. A., O. M. Ogunyemi, I. M. Ibrahim, S. O. Afolabi, and J. O. Adebayo, "Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective", Computers in biology and medicine, vol. 134: Elsevier, pp. 104406, 2021. Abstract
n/a
Rania M. Hathout, AbdelKader A. Metwally, Sherweit H. El-Ahmady, Eman S. Metwally, Noha A. Ghonim, Salma A. Bayoumy, T. Erfan, Rosaline Ashraf, M. Fadel, Abdullah I. El-Kholy, et al., "Dual stimuli-responsive polypyrrole nanoparticles for anticancer therapy", Dual stimuli-responsive polypyrrole nanoparticles for anticancer therapy, vol. Volume 47, , issue October 2018, pp. 176-180, 2018.
Hassan, H. A. F. M., L. Smyth, J. T. - W. Wang, P. M. Costa, K. Ratnasothy, S. S. Diebold, G. Lombardi, and K. T. Al-Jamal, "Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy", Biomaterials, vol. 104: Elsevier, pp. 310-322, 2016. Abstract
n/a
Farag, A., A. M. Eldeib, and S. Yamany, "Dual Stage vs. Single Stage Multi-Modal Medical Volumes Registration", International Conference on Image Processing - ICIP 2000, Vancouver Convention & Exposition Centre, Vancouver, British Columbia, Canada, September 10-13,, 2000.
Helal, K., S. Attia, H. Fahmy, T. Ismail, Y. Ismail, and H. Mostafa, "Dual Split-Merge: A High Throughput Router Architecture for FPGAs", Elsevier Microelectronics Journal, vol. 81, pp. 51-57, 2018. [PDF]
Helal, K., S. Attia, H. A. H. Fahmy, T. Ismail, Y. Ismail, and H. Mostafa, "Dual Split-Merge: A high throughput router architecture for FPGAs", Microelectronics Journal, vol. 81: Elsevier, pp. 51–57, 2018. Abstract
n/a
Ibrahim, M. A. A., M. R. Elhebeary, M. M. Aboudina, and A. N. Mohieldin, "A Dual Source Microscale Energy Harvesting System for Wireless Sensor Networks", Industrial Electronics, IEEE International Symposium on, Búzios, Rio de Janeiro, Brazil, Submitted.
Elhebeary, M. R., M. A. A. Ibrahim, M. M. Aboudina, and A. N. Mohieldin, "A dual source microscale energy harvesting system for wireless sensor networks", Industrial Electronics (ISIE), 2015 IEEE 24th International Symposium on: IEEE, pp. 140–145, 2015. Abstract
n/a
Elhebeary, M. R., M. A. A. Ibrahim, M. M. Aboudina, and A. N. Mohieldin, "A Dual Source Microscale Energy Harvesting System for Wireless Sensor Networks", International Symposium on Industrial Electronics (ISIE), Brazil, June, 2015.
Yakoot, M., M. H. El-Shabrawi, M. M. AbdElgawad, A. A. Mahfouz, S. Helmy, A. M. Abdo, and H. R. El-Khayat, "Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection.", Journal of pediatric gastroenterology and nutrition, 2018 Mar 22. Abstract

OBJECTIVES: Dual sofosbuvir/daclatasvir (SOF/DCV) therapy is currently recommended by The European Association for Study of Liver (EASL) as an option for the treatment of chronic hepatitis C virus infection (HCV) in adults for all genotypes; however it is still not considered for patients younger than 18 years old. We aimed to test safety and efficacy of SOF/DCV in adolescent patients 12 to 17 years old with chronic HCV, genotype 4 infection.

METHODS: We conducted a prospective, uncontrolled, open-label multicenter study. A total of 30 chronic HCV infected adolescents, aged from 12 to 17 years old were included and treated with dual SOF/DCV for 12 weeks. Patients were monitored throughout the treatment and follow-up period for safety and efficacy outcome measures including the sustained virologic response 12 (SVR12) rate.

RESULTS: The Intention to treat (ITT) SVR12 rate was 29/30 (96.7%; 95% confidence interval (CI): 83.3 - 99.4%). The only patient who did not achieve SVR12 was lost to follow up after showing viral negativity at the end of treatment visit. While all the remaining 29 patients (100%, 95% CI: 88.3 - 100%) who completed the follow up visits achieved SVR12. All patients showed normalized liver enzymes with normal hematological, liver and renal function tests at the end of the study. No fatalities or treatment-emergent serious or severe adverse events were reported throughout the study.

CONCLUSIONS: Sofosbuvir/Daclatasvir combined therapy could be a safe and effective treatment in adolescent patients 12 to 17 years old with chronic HCV genotype 4 infection.

T
Aziz, A. M. T. A., and H. M. E. Zahed, "THE DUAL ROLE OF VITAMIN D IN OSTEOPOROSIS TREATMENT ", THE EGYPTIAN JOURNAL OF MEDICAL SCIENCES , vol. 39, issue 1, pp. 85-93 , 2018. Abstractthe_dual_role_of_vitamin_d_in_osteoporosis_treatment.pdf

Background: Osteoporosis is a condition characterized by low bone mass and increased bone fragility, and increase the risk of fractures. Osteoporosis is attributed to interaction between endocrine, metabolic and mechanical factors. proinflammatory cytokines are involved in the regulation of osteoblasts and osteoclasts. There is growing evidence that vitamin D3 deficiency could be a contributing factor in the development of different chronic diseases and their complications. Vitamin D plays an im-portant role in normal calcium and bone homeostasis though stimulation of new bone formation and suppression of the production of pro-inflammatory cytokines.
Methods: fifty rats were included in the experiment and were divided in to five groups of ten rats in each group as the following:
group1: control group; group2: induced osteoporosis group; group3: induced osteoporosis received vitamin D for one month; group4: induced osteoporosis received vitamin D for two months; group 5: induced osteoporosis received vitamin D for three months. Serum samples were collected for estimation of inflammatory cytokines (IL1, IL 6, and TNF) and inflammatory cytokines (IL10 and IL13) and bone marker (RANKL, os-teocalcin, and ALP) by ELISA technique.
Results: vitamin D treatment suppress the inflammation and im-prove the immune system in addition to stimulation of new bone formation through inhibition of RANKL and stimulation of osteocalcin and ALP.
Conclusion: vitamin D can be considered an effective therapeutic agent for osteoporosis.

D
Ahmed, O., A. Farid, and A. El Amir, "Dual role of melatonin as an anti-colitis and anti-extra intestinal alterations against acetic acid-induced colitis model in rats", Scientific Reports , vol. 12, issue 1, pp. 1-12, 2022.
and 8. F. Amer, K. Mostafa, M. T., "Dual Robust Color Image Watermarking System", Egyptian Informatics Journal, vol. 5, issue 1, 2004. Abstract
n/a
Ragab, D., D. M. Abdallah, and H. S. El-Abhar, "The dual reno- and neuro-protective effects of dimethyl fumarate against uremic encephalopathy in a renal ischemia/reperfusion model", Pharmacol Rep., vol. 72, issue (4), pp. :969-983., 2020.
Elsisi, M., M. Soliman, M. A. S. Aboelela, and W. Mansour, "Dual Proportional Integral Controller of Two-Area Load Frequency Control Based Gravitational Search Algorithm", TELKOMNIKA Indonesian Journal of Electrical Engineering, vol. 15, issue 1, pp. 24-35, 2015. dual_proportional_integral_controller.pdf
SOLIMAN, D. R. S. H. E. H. A. B., "Dual plane: Breast Augmentation with Circumareolar Mastopexy: Indications, Benefits, and Outcomes", Kasr El Aini Journal of Surgery, vol. 14, issue 1, 2013.
ABDELNABY, R. A. N. A. M., H. E. B. A. S. RATEB, O. Ali, A. S. Saad, R. I. Nadeem, S. M. Abou-Seri, K. M. Amin, N. S. Younis, and R. Abdelhady, "Dual PI3K/Akt Inhibitors Bearing Coumarin-Thiazolidine Pharmacophores as Potential Apoptosis Inducers in MCF-7 Cells.", Pharmaceuticals (Basel, Switzerland), vol. 15, issue 4, 2022. Abstract

Breast cancer is the most common malignancy worldwide; therefore, the development of new anticancer agents is essential for improved tumor control. By adopting the pharmacophore hybridization approach, two series of 7-hydroxyl-4-methylcoumarin hybridized with thiosemicarbazone () and thiazolidin-4-one moieties () were prepared. The in vitro anticancer activity was assessed against MCF-7 cells adopting the MTT assay. Nine compounds showed significant cytotoxicity. The most promising compound, , induced remarkable cytotoxicity (IC of 1.03 + 0.05 µM). Further investigations were conducted to explore its pro-apoptotic activity demonstrating S-phase cell cycle arrest. Apoptosis rates following treatment revealed a 5-fold and 100-fold increase in early and late apoptotic cells, correspondingly. Moreover, our results showed caspase-9 dependent apoptosis induction as manifested by an 8-fold increase in caspase-9 level following treatment. Mechanistically, was found to target the PI3K-α/Akt-1 axis, as evidenced by enzyme inhibition assay results reporting significant inhibition of examined enzymes. These findings were confirmed by Western blot results indicating the ability of to repress levels of Cyclin D1, p-PI3K, and p-Akt. Furthermore, docking studies showed that has a binding affinity with the PI3K binding site higher than the original ligands X6K. Our results suggest that has pharmacological potential as a promising anti-cancer compound by the inhibition of the PI3K/Akt axis.

Tourism